Oral anticoagulation for cerebral ischemia of arterial origin: High initial bleeding risk

Neurology

Volumn 57, Issue 11, 2001, Pages 1993-1999

  Torn, M ^a   Algra, A ^b   Rosendaal, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; NETHERLANDS; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL;

EID: 0035846584     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.11.1993     Document Type: Article

References (20)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled
2. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction
3. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
4. The effect of warfarin on mortality and reinfarction after myocardial infarction
5. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
6. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
7. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors
8. Management of anticoagulant therapy: The Dutch experience
9. Hemostasis ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulation control
10. A method to determine the optimal intensity of oral anticoagulant therapy
11. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
12. Bleeding during antithrombotic therapy in patients with atrial fibrillation
13. The Scylla and Charybdis of oral anticoagulant treatment
14. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
15. Pathogenesis of leukoaraiosis: A review
16. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses
17. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation
18. Optimal intensity of oral anticoagulant therapy after myocardial infarction
19. Optimal oral anticoagulant therapy in patients with mechanical heart valves
20. Design of ESPRIT an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin